NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months One patient achieved a CR and nine patients achieved a PR, of which four were confirmed PRs. Median duration of response on the five confirmed...
Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 14, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
- Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; enrollment for the dose-expansion is ongoing - Merck initiated IND-enabling toxicology studies for the first program under the cytokine derivatives collaboration...
7th Annual Truist Securities Life Sciences Summit – Presentation
Webcast, Click Here Download Presentation, Click Here
Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., April 20, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...
20th Annual Needham Virtual Healthcare Conference – Presentation
Webcast, Click Here Download Presentation, Click Here
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
– Initiation of an IND enabling toxicology study for the first program under the 2018 collaboration oncytokine derivatives earns a $15 million milestone payment from Merck SOUTH SAN FRANCISCO, Calif., April 15, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 8, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Open Letter from CEO, Bill Newell
I Stand in Support of our AAPI Community I want to address the violence and discrimination towards our AAPI community; it has been there for hundreds of years. It is now apparent that it was, in some cases, under-reported or ignored. Most certainly it was greatly...
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
SOUTH SAN FRANCISCO, Calif., March. 22, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...